Moneyta · stock research · no sign-up needed
REGN
FollowFigures below come straight from SEC filings: every number is the company's own, on the record.
Revenue (Q2 FY2026)
$4.3B
+41.7% y/y
Net income (Q2 FY2026)
$1.3B
as filed with the SEC
Institutions holding
1,347
-61 last quarter
Overview · REGENERON PHARMACEUTICALS, INC.
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat neovascular age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent inject…
Management team
- Mr. Joseph J. LaRosa · Executive VP, General Counsel & SecretaryFind on LinkedIn
- Mr. Ryan Crowe · Senior Vice President of Investor Relations & Strategic AnalysisFind on LinkedIn
- Mr. Christopher R. Fenimore CPA · Senior VP of Finance & CFOFind on LinkedIn
- Mr. Bob McCowan · Senior VP of IT & Chief Information OfficerFind on LinkedIn
Start free to see the full management team.
Links open LinkedIn searches, not verified profiles. Team data from our market-data vendor's company profile.
What history says when its signals fire
Every signal Moneyta surfaces carries its full base-rate history: how often it beat the index, and how often it didn't. See the evidence
The desk's Snapshot
3 of 15 open to everyone · members see allRead the full desk report on REGN
Seven analysts, the debate, the risk review, every claim cited. And the same for every name you hold.
Free plan, no credit card required. Silver opens the full report, $19.99 a month. AI-written · every claim cites a source · Insight, not advice.
The full desk report
Seven AI analysts read the filings and argue both sides. What survives, with every claim cited, for members.
Who holds it, who's buying Gold
Full holder table, quarter-over-quarter flows, insider transactions, and the conviction screen.
Largest holder
Net flow last quarter
Insider buys, 90d
Further reading
Source: SEC EDGAR (XBRL company facts, form 13F-HR). Educational analysis of published data: insight, not advice.